Michael D. Press, Ph.D.
Affiliations: | 2007 | Harvard University, Cambridge, MA, United States |
Area:
Archaeology AnthropologyGoogle:
"Michael Press"Parents
Sign in to add mentor| Lawrence E. Stager | grad student | 2007 | Harvard | |
| (Philistine figurines and figurines in Philistia in the Iron Age.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Vogel CL, Cobleigh MA, Tripathy D, et al. (2023) Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of -Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 1638-1645 |
| Kachuri L, Du Z, Weinhold N, et al. (2019) Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans Blood. 134: 4379-4379 |
| Press M, Seoane J, Curtis C, et al. (2019) Abstract PD3-11:HER2/ERBB2status in “HER2equivocal” breast cancers by FISH and ASCO-CAP guidelines: False-positives due to heterozygous deletions of alternative control loci Cancer Research |
| Hurvitz S, Martin M, Press M, et al. (2019) Abstract PD2-10: Treatment with abemaciclib modulates the immune response in gene expression analysis of the neoMONARCH neoadjuvant study of abemaciclib in postmenopausal women with HR+, HER2 negative breast cancer Cancer Research. 79 |
| Caswell-Jin J, McNamara K, Reiter J, et al. (2019) Abstract P3-06-01: Clonal evolution and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy Cancer Research. 79 |
| Chen H-, Euw EV, Millan P, et al. (2019) Results from TRIO030, a pre-surgical tissue-acquisition study to evaluate molecular alterations in human breast cancer tissue following short-term exposure to the androgen receptor antagonist darolutamide Annals of Oncology. 30 |
| Ring A, Nguyen C, Smbatyan G, et al. (2018) CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer. Cancers. 10 |
| Martin M, Hurvitz S, Chan D, et al. (2018) Abstract PD5-01: Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC) Cancer Research. 78 |
| Prat A, Slamon D, Hurvitz S, et al. (2018) Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC) Cancer Research. 78 |
| Wu N, Wong E, Acca B, et al. (2018) Abstract P2-03-03: A multicenter clinical study of Xpert® breast cancer STRAT4 demonstrates high concordance with central lab ER, PgR, HER2, and Ki67 IHC and HER2 FISH tests in FFPE breast tumor tissues Cancer Research. 78 |